Featured Reviews and Press Releases
 

Featured Reviews and Press Releases

  • Osteoarthritis is a disease of the joints, commonly found in knees, hips, and hands. When the joint loses cartilage, the bone grows to try and repair the damage but this bone growth is abnormal and makes things worse. Osteoarthritis is one of the leading causes of disability as it is painful and affects physical function and ability to use the...
    3 March 2015
  • New evidence helps health workers in the fight against EbolaEmbargoed: 00.01 GMT: Thursday 26th February 2015 Press contact: Jo AnthonyM+44(0) 7582 726 634E janthony@cochrane.org or pressoffice@cochrane.org   Watch a short film which accompanies this Cochrane Review and talks about applying the findings in relevant clinical settings.One year after...
    24 February 2015
  • Time magazine cites a 2012 Cochrane Review in an article discussing foods which may help to lower blood pressure.
    24 February 2015
  • Every Cochrane Review reflects both a substantial commitment of time and expertise on the part of the review author team and all the editors, information specialists and peer reviewers based at the relevant Cochrane Review Group. The work undertaken and the rigour of the process are both focused on ensuring that the best quality evidence from...
    30 January 2015
  • Cochrane Review shows how a cheaper alternative to licensed drug for treating eye disease has similar side effectsNeovascular macular degeneration is a progressive and chronic disease of the eye, and a leading cause of blindness in older people globally.About one in 10 people with macular degeneration suffers legal blindness.In September 2014, a...
    30 January 2015
  • In a recent story, US-based Fox News discusses the publication of a number of major studies, including a Cochrane Review, assessing aspects of smoking addiction and behaviour, and how the results might be integrated for effective public health intervention. The story looks at the results of two surveys published in December 2014, both aimed at...
    30 January 2015
  • Since 2002, governments around the world have spent billions of dollars stockpiling neuraminidase inhibitors (NIs) such as Tamiflu® (oseltamivir) and Relenza® (zanamivir) in anticipation of an influenza pandemic. This trend increased dramatically following the outbreak of the H1N1 virus (swine flu) in April 2009. It was initially believed that NIs...
    9 May 2014

Pages